RecruitingNCT05062707

Early Ageing During Therapy in AYA Cancer Patients

Longitudinal Assessment of Therapy-related Early Ageing in Adolescent and Young Adult (AYA) Cancer Patients

Sponsor

University Medical Center Groningen

Enrollment

120 participants

Start Date

Feb 10, 2022

Study Type

OBSERVATIONAL

Conditions

Breast Cancer Cervical Cancer Cancer Hodgkin Lymphoma Osteosarcoma Ewing Sarcoma Testicular Cancer Leukemia

Summary

Longitudinal cohort study; measurements before start of systemic therapy and one year later.

Eligibility

Min Age: 18 YearsMax Age: 39 Years

Inclusion Criteria3

Aged 18-39 years at cancer diagnosis
Having a histologically and/or cytologically confirmed cancer diagnosis, including leukemia, (non-)Hodgkin lymphoma, testicular cancer, osteosarcoma, Ewing sarcoma, breast cancer, and cervical cancer.
Scheduled to start systemic therapy with curative intent. Allowed treatments (concurrent or sequential) are: surgery, radiotherapy, chemotherapy, antibodies.

Exclusion Criteria3

patients who are not able to understand the patient information letter and informed consent form
patients who will be treated with immune checkpoint inhibitors or targeted therapy with inhibitors of angiogenesis
patients who have been treated with systemic therapy or radiotherapy for a previous malignancy (exceptions: in situ carcinoma of the cervix or uterus and adequately treated basal and squamous cell carcinoma of the skin).

Interventions

PROCEDUREBlood sampling

Study measurements will be performed twice and consist of blood withdrawal and physical examination (weight, height, waist-hip ratio, and blood pressure).